Prostate cancer constitutes a major health problem in Western countries. It is the most frequently diagnosed cancer among men and the second leading cause of male cancer deaths. The identification of key molecular alterations in prostate-cancer cells implicates carcinogen defenses (GSTP1), growth-factor-signaling pathways (NKX3.1, PTEN, and p27), and androgens (AR) as critical determinants of the phenotype of prostate-cancer cells. Glutathione S-transferases (GSTP1) are detoxifying enzymes. Cells of prostatic intraepithelial neoplasia, devoid of GSTP1, undergo genomic damage mediated by carcinogens. NKX3.1, PTEN, and p27 regulate the growth and survival of prostate cells in the normal prostate. Inadequate levels of PTEN and NKX3.1 lead to a reduction in p27 levels and to increased proliferation and decreased apoptosis. Androgen receptor (AR) is a transcription factor that is normally activated by its androgen ligand. During androgen withdrawal therapy, the AR signal transduction pathway also could be activated by amplification of the AR gene, by AR gene mutations, or by altered activity of AR coactivators. Through these mechanisms, tumor cells lead to the emergence of androgen-independent prostate cancer.

Human Diseases; Cancer: specific types
BRITE hierarchy

PMID:12878745

Nelson WG, De Marzo AM, Isaacs WB.

Prostate cancer.

N Engl J Med 349:366-81 (2003)
DOI:10.1056/NEJMra021562

PMID:15724144

Li L, Ittmann MM, Ayala G, Tsai MJ, Amato RJ, Wheeler TM, Miles BJ, Kadmon D, Thompson TC.

The emerging role of the PI3-K-Akt pathway in prostate cancer progression.

Prostate Cancer Prostatic Dis 8:108-18 (2005)
DOI:10.1038/sj.pcan.4500776

PMID:16551847

Pienta KJ, Bradley D.

Mechanisms underlying the development of androgen-independent prostate cancer.

Clin Cancer Res 12:1665-71 (2006)
DOI:10.1158/1078-0432.CCR-06-0067

PMID:11900250

Feldman BJ, Feldman D.

The development of androgen-independent prostate cancer.

Nat Rev Cancer 1:34-45 (2001)
DOI:10.1038/35094009

PMID:15082523

Heinlein CA, Chang C.

Androgen receptor in prostate cancer.

Endocr Rev 25:276-308 (2004)
DOI:10.1210/er.2002-0032

PMID:9422516

Koivisto P, Kolmer M, Visakorpi T, Kallioniemi OP.

Androgen receptor gene and hormonal therapy failure of prostate cancer.

Am J Pathol 152:1-9 (1998)

PMID:10835690

Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, Feldman D.

Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor.

Nat Med 6:703-6 (2000)
DOI:10.1038/76287

PMID:10453277

Macri E, Loda M.

Role of p27 in prostate carcinogenesis.

Cancer Metastasis Rev 17:337-44 (1998)
DOI:10.1023/A:1006133620914

PMID:11750244

Steers WD.

5alpha-reductase activity in the prostate.

Urology 58:17-24; discussion 24 (2001)
DOI:10.1016/S0090-4295(01)01299-7

PMID:8069858

Lin D, Meyer DJ, Ketterer B, Lang NP, Kadlubar FF.

Effects of human and rat glutathione S-transferases on the covalent DNA binding of the N-acetoxy derivatives of heterocyclic amine carcinogens in vitro: a possible mechanism of organ specificity in their carcinogenesis.

Cancer Res 54:4920-6 (1994)

PMID:11527574

Grimes CA, Jope RS.

The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling.

Prog Neurobiol 65:391-426 (2001)
DOI:10.1016/S0301-0082(01)00011-9

PMID:21747944

Leshem O, Madar S, Kogan-Sakin I, Kamer I, Goldstein I, Brosh R, Cohen Y, Jacob-Hirsch J, Ehrlich M, Ben-Sasson S, Goldfinger N, Loewenthal R, Gazit E, Rotter V, Berger R

TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model.

PLoS One 6:e21650 (2011)
DOI:10.1371/journal.pone.0021650

PMID:20478527

Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X, Wu L, Li J, Hu M, Gong Y, Cheng H, Laxman B, Vellaichamy A, Shankar S, Li Y, Dhanasekaran SM, Morey R, Barrette T, Lonigro RJ, Tomlins SA, Varambally S, Qin ZS, Chinnaiyan AM

An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.

Cancer Cell 17:443-54 (2010)
DOI:10.1016/j.ccr.2010.03.018

PMID:19399032

Squire JA

TMPRSS2-ERG and PTEN loss in prostate cancer.

Nat Genet 41:509-10 (2009)
DOI:10.1038/ng0509-509

PMID:25915839

Adamo P, Ladomery MR

The oncogene ERG: a key factor in prostate cancer.

Oncogene 35:403-14 (2016)
DOI:10.1038/onc.2015.109

PMID:25485532

Burdova A, Bouchal J, Tavandzis S, Kolar Z

TMPRSS2-ERG gene fusion in prostate cancer.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 158:502-10 (2014)
DOI:10.5507/bp.2014.065

PMID:18172298

Helgeson BE, Tomlins SA, Shah N, Laxman B, Cao Q, Prensner JR, Cao X, Singla N, Montie JE, Varambally S, Mehra R, Chinnaiyan AM

Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.

Cancer Res 68:73-80 (2008)
DOI:10.1158/0008-5472.CAN-07-5352

PMID:28968951

Kim H, Datta A, Talwar S, Saleem SN, Mondal D, Abdel-Mageed AB

Estradiol-ERbeta2 signaling axis confers growth and migration of CRPC cells through TMPRSS2-ETV5 gene fusion.

Oncotarget 8:62820-62833 (2017)
DOI:10.18632/oncotarget.11355